Matrixdock Expands Tokenized Silver (XAGm) to Sui, Enabling Institutional-Grade Access for On-Chain Finance

Institutional-grade Silver is now accessible on Sui, expanding XAGm's use in on-chain financial systems

SINGAPORE, May 12, 2026 /PRNewswire/ -- Matrixdock today announced the expansion of its tokenized silver product, XAGm, to Sui, extending its on-chain commodities offering beyond Ethereum. The move enables institutional-grade silver to be actively used across trading, lending, and collateralized applications, reflecting a broader shift in on-chain finance from asset issuance toward real financial execution.

A new phase of on-chain finance is emerging. Real-world assets (RWAs) are no longer defined by their ability to be tokenized, but by their ability to function—moving, interacting, and serving as collateral within programmable financial systems.

Sui is a next-generation Layer 1 blockchain built for scalable finance and global payments. It makes assets, permissions, and user data programmable and ownable, thereby serving as the ideal platform for broader utilization of RWAs. Matrixdock complements this foundation by serving the reserve layer for on-chain finance—bringing institutional-grade assets on-chain with transparency, asset integrity, and real utility.

Today, this shared vision advances as Matrixdock brings Matrixdock Silver (XAGm) to Sui, extending its collaboration beyond tokenized gold into a greater on-chain commodities strategy.

XAGm is a fully allocated, institutional-grade tokenized silver asset backed by London Bullion Market Association (LBMA)-accredited silver. Natively issued on Sui, each token is directly linked to underlying vaulted bullion, supported by independent verification and professional custody. By bringing silver on-chain, XAGm transforms a traditionally static asset into one that can move seamlessly across trading, lending, and collateralized financial applications.

Despite growing demand for silver exposure, institutional-grade on-chain silver remains scarce. Existing products often lack verifiable reserves, sufficient liquidity, or the ability to integrate into financial applications.

The Sui Foundation has indicated plans to allocate a portion of its treasury into XAGm, signaling alignment and confidence in tokenized silver as a reserve-grade asset within on-chain financial infrastructure.

From Issuance to Execution

Ethereum established the foundation for tokenized assets–prioritizing transparency, composability, and market access. Within this environment, XAGm demonstrated that institutional-grade commodities can exist on-chain with verifiable backing.

Sui represents the next phase.

With its horizontally scalable architecture, parallel execution engine, and sub-second finality, Sui enables assets to operate within high-performance financial systems — where they are not only issued, but actively used. This marks a broader transition in blockchain design: from passive issuance layers to execution environments capable of supporting real-time financial activity at scale.

This transition is driven by two forces: growing demand for reliable collateral in DeFi, and the emergence of high-performance blockchains capable of supporting real-time financial activity.

"Tokenized assets are at the forefront of this new era of global finance, where assets move at the speed of messages, and Sui is uniquely positioned to underpin and power all the necessary components at scale," said Adeniyi Abiodun, Co-Founder and Chief Product Officer at Mysten Labs, the original contributors to Sui. "We're pleased to work with Matrixdock to expand into its tokenized silver product, XAGm."

Silver as a Functional Asset

Unlike gold, which primarily serves as a store of value, silver presents a fundamentally different profile. Its industrial demand and higher volatility make it structurally suited for active financial use.

"Gold proved that real-world assets can exist on-chain. Silver is where they start to function," said Eva Meng, Head of Matrixdock.

"Following gold, silver represents the next evolution of on-chain commodities—where liquidity, utility, and programmability converge. With XAGm, we are enabling silver to function as institutional-grade collateral across decentralized markets, without compromising on transparency or asset integrity. There are very few spot silver assets today that meet the requirements of DeFi at an institutional standard, and this is the gap XAGm is designed to fill. Sui's architecture allows us to deliver this at scale."

XAGm introduces Matrixdock's Fungible Reserve Standard (FRS), an issuance framework that preserves fungibility while reconciling token supply with underlying reserves as real-world carry is recognized over time. This ensures that token supply remains consistently aligned with underlying assets without introducing hidden risk or compromising composability across DeFi.

As on-chain derivatives markets evolve–particularly with rising demand for silver perpetuals–the need for underlying spot assets that can support trading, hedging, and collateralization becomes essential. Assets such as XAGm are no longer optional–they become foundational infrastructure.

Infrastructure Designed to Scale

Sui's parallel execution model, sub-second finality, and horizontally scalable infrastructure enable instantaneous, cost-efficient transactions — critical for high-frequency financial use cases and collateral movement. Its security and reliability provide the foundation for global-scale adoption of tokenized real-world assets.

This shift — from issuance to execution, from representation to utility — reflects a structural redefinition of how real-world assets participate in financial systems. Together, Matrixdock and Sui are advancing a shared vision: reserve-grade assets that are transparent, verifiable, and natively integrated into internet capital markets.

About Sui

Sui, where money moves as freely as messages, is a next-generation Layer 1 blockchain built for scalable finance and global payments. Founded by the core team behind Meta's stablecoin initiative and powered by an object-centric model, Sui makes assets, permissions, and user data programmable and ownable. Sui's primitives offer builders everything they need to create high-performance payments and financial applications, including instant agentic payments. Learn more at sui.io.

Contact: media@sui.io

About Matrixdock

Matrixdock is Asia's leading real-world asset (RWA) tokenization platform, focused on bringing institutional-grade assets onto on-chain capital markets through fully allocated, transparent and verifiable structures.

Its products include Matrixdock Gold (XAUm) and Silver (XAGm), each backed 1:1 by LBMA-accredited bullion with token-to-bar allocation, and STBT, a tokenized short-term U.S. Treasury product designed for on-chain liquidity and collateral use. All assets are held in professional custody, independently verified, with full transparency and integration across leading blockchain ecosystems.

Matrixdock also partners with sovereign and institutional initiatives, including the architecture and technical development of TER, the world's first sovereign-backed gold token for Gelephu Mindfulness City (GMC) in the Kingdom of Bhutan.

Matrixdock is building the reserve layer for on-chain capital markets.

Matrixdock official website: https://www.matrixdock.com/

Contact: support@matrixdock.com

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

Matrixdock Expands Tokenized Silver (XAGm) to Sui, Enabling Institutional-Grade Access for On-Chain Finance

In the news release, CordenPharma Boosts Aseptic Fill-Finish Capacity to 500 Million Sterile Injectable Units Per Year, issued 10-Sep-2026 by CordenPharma over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows, with additional details at the end:

CordenPharma Boosts Aseptic Fill-Finish Capacity to 500 Million Sterile Injectable Units Per Year

CordenPharma accelerates sterile injectable CDMO manufacturing expansion with €80 million multi-year investment in new facility and additional aseptic fill & finish lines

BASEL, Switzerland, Sept. 10, 2026 /PRNewswire/ -- CordenPharma continues its ambitious long-term injectable CAPEX program at its FDA & EMA-approved Caponago (Milan), Italy site, reinforcing its position as a global leader in sterile injectable manufacturing. The expansion involves two key components to augment manufacturing capacity for sterile injectable drug products.

Firstly, the company has committed a multi-year €80 million investment into the future of injectable drug products, marking a significant milestone of that total with a €13 million acquisition of a new 11,000 m² commercial building and 26,000 m² of land, adjacent to its existing late-stage aseptic fill & finish manufacturing area. This expansion was finalized on 28 July 2026, increasing the site footprint by greater than 50%.

The new facility offers a blank canvas ideal for innovators seeking fit-for-purpose aseptic fill & finish CDMO outsourcing of their peptide, LNP, small molecule, biologic, and oligonucleotide-based injectable therapeutics, tailored to their specific production setups and requirements. The expanded capacity is a versatile foundation for the integration of additional manufacturing lines supporting a wide range of injectable formats including Pre-Filled Syringes (PFS), liquid or lyophilized vials, cartridges, and auto-injectors. Customers will also benefit from a single-site offering injectable solutions integrated with LNP manufacturing capabilities on the same campus at CordenPharma Caponago.

The space can accommodate a minimum of four aseptic fill & finish lines, four visual inspection lines, and four additional packaging lines, with options for customer-owned lines, large-scale lyophilization, and auto-injector assembly.

Secondly, over the past two years, CordenPharma has embarked on a series of strategic expansions at an existing operational area within its Caponago site that immediately contributes to the increased injectable capacity by adding two new aseptic fill & finish isolator lines. These include:

• A clinical and small-scale commercial combo line from Bausch & Ströbel for Pre-Filled Syringes (PFS), vials, and cartridges.
• A high-speed PFS & cartridge line from Syntegon, capable of producing >500,000 units per day.
• Expansion of the automatic secondary packaging area for PFS, vials, and ampoules.
• A doubling of analytical capacity to support growing project pipelines.

Completion of the new isolator lines is targeted for mid-2027 and 2028 respectively, ensuring CordenPharma remains at the forefront of sterility assurance and long-term compliance during sterile injectable manufacturing.

The investment in these new and expanded facilities underscores a proactive approach to addressing the global healthcare industry's increasing need for specialized injectable manufacturing. With these combined investment milestones bolstering a landmark scale-up in production with a projected total capacity up to 500 million injectable units per year, CordenPharma is poised to support innovators across their injectable drug lifecycle from early-phase projects to large-scale commercial production.

This capacity surge helps meet the rising global demand for sterile injectable outsourcing across therapeutic areas such as oncology, obesity, diabetes and Inflammatory diseases with complex modalities such as peptide-based GLP-1 therapeutics, oligonucleotides, LNPs, biosimilars and other biologics.

The company's customers will also gain valuable access to integrated solutions from drug substance to drug products, leveraging CordenPharma's global facility network and expertise in manufacturing peptides (including oral peptide drug products), oligonucleotides, non-viral carriers such as LNPs, and small molecules, including both highly potent and non-potent APIs.

Dr. Michael Quirmbach, President & CEO of CordenPharma Group, commented: "The support of our shareholders, Astorg, underscores our commitment to advancing sterile injectable manufacturing at CordenPharma Caponago. This strategic investment strengthens our leadership in the manufacture of drug products using complex modalities and enhances our end-to-end supply capabilities to meet rising global demand for injectable outsourcing, ultimately enabling partners to bring vital drug products in key therapeutic areas to patients more efficiently."

About CordenPharma

CordenPharma is a CDMO supporting and partnering with biotech and pharma innovators of complex modalities in the advancement of their drug development lifecycle. Harnessing the collective expertise of the teams across its globally integrated facility network, CordenPharma provides bespoke outsourcing services spanning the complete supply chain, from early clinical-phase development to commercialization.

With scientific expertise and partnership at its core, CordenPharma provides customers with high-value, end-to-end services with a strategic focus on Peptides, Small Molecules (both Highly Potent and Regular Potency), customized Lipid Excipients, Lipid NanoParticles (LNPs), sterile Injectables, and Oligonucleotides.

The CordenPharma Group is comprised of 13 facilities across Europe, North America and Asia with more than 3,500 employees. In the 2025 financial year, the organization generated sales of €960 million. In 2022, CordenPharma was acquired by Astorg - a leading Pan-European private equity firm with deep expertise in the healthcare sector - to accelerate its development and further strengthen its leadership in the CDMO space.

Please visit cordenpharma.com for more information I Follow CordenPharma on LinkedIn.

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

CordenPharma Boosts Aseptic Fill-Finish Capacity to 500 Million Sterile Injectable Units Per Year